NYSEAMERICAN:XTNT Xtant Medical (XTNT) Stock Price, News & Analysis $0.47 +0.00 (+0.64%) Closing price 05/2/2025 04:10 PM EasternExtended Trading$0.48 +0.01 (+1.69%) As of 05/2/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock About Xtant Medical Stock (NYSEAMERICAN:XTNT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Xtant Medical alerts:Sign Up Key Stats Today's Range$0.39▼$0.4850-Day Range$0.38▼$0.5952-Week Range$0.33▼$0.96Volume271,846 shsAverage Volume95,522 shsMarket Capitalization$65.61 millionP/E RatioN/ADividend YieldN/APrice Target$2.25Consensus RatingBuy Company OverviewXtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana.Read More… Xtant Medical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreXTNT MarketRank™: Xtant Medical scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingXtant Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXtant Medical has received no research coverage in the past 90 days.Read more about Xtant Medical's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Xtant Medical is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xtant Medical is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXtant Medical has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Xtant Medical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.05% of the float of Xtant Medical has been sold short.Short Interest Ratio / Days to CoverXtant Medical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xtant Medical has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXtant Medical does not currently pay a dividend.Dividend GrowthXtant Medical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.05% of the float of Xtant Medical has been sold short.Short Interest Ratio / Days to CoverXtant Medical has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xtant Medical has recently increased by 7.28%, indicating that investor sentiment is decreasing significantly. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Xtant Medical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.70% of the stock of Xtant Medical is held by insiders.Percentage Held by Institutions69.33% of the stock of Xtant Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xtant Medical's insider trading history. Receive XTNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xtant Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address XTNT Stock News HeadlinesXtant Medical Launches Trivium™ Advanced Bone Graft for Superior PerformanceApril 23, 2025 | prnewswire.comXtant Medical secures investor support, projects Q1 revenue growthApril 18, 2025 | uk.investing.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 4, 2025 | Porter & Company (Ad)Xtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65MApril 17, 2025 | markets.businessinsider.comXtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%April 16, 2025 | prnewswire.comXtant Medical price target lowered to $2 from $3 at BTIGMarch 8, 2025 | markets.businessinsider.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 7, 2025 | finanznachrichten.deSee More Headlines XTNT Stock Analysis - Frequently Asked Questions How have XTNT shares performed this year? Xtant Medical's stock was trading at $0.4681 on January 1st, 2025. Since then, XTNT shares have increased by 0.8% and is now trading at $0.4720. View the best growth stocks for 2025 here. How were Xtant Medical's earnings last quarter? Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) released its quarterly earnings results on Tuesday, November, 12th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.02. The medical device company earned $27.94 million during the quarter. Xtant Medical had a negative net margin of 15.45% and a negative trailing twelve-month return on equity of 37.07%. Read the conference call transcript. When did Xtant Medical's stock split? Xtant Medical shares reverse split on the morning of Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Xtant Medical? Shares of XTNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xtant Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xtant Medical investors own include Meta Platforms (META), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA) and Broadcom (AVGO). Company Calendar Last Earnings11/12/2024Today5/04/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:XTNT Previous SymbolAMEX:XTNT CIK1453593 Webxtantmedical.com Phone(406) 388-0480Fax406-388-1354Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$3.00 Low Stock Price Target$1.50 Potential Upside/Downside+376.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$660,000.00 Net Margins-15.45% Pretax Margin-14.79% Return on Equity-37.07% Return on Assets-18.47% Debt Debt-to-Equity Ratio0.42 Current Ratio2.12 Quick Ratio0.88 Sales & Book Value Annual Sales$91.30 million Price / Sales0.72 Cash Flow$0.02 per share Price / Cash Flow20.06 Book Value$0.39 per share Price / Book1.21Miscellaneous Outstanding Shares139,010,000Free Float125,524,000Market Cap$65.61 million OptionableNot Optionable Beta0.35 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSEAMERICAN:XTNT) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xtant Medical Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xtant Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.